ABBV vs. AMGN, GILD, MRNA, ABT, BMY, JNJ, LLY, MRK, PFE, and ZTS
Should you be buying AbbVie stock or one of its competitors? The main competitors of AbbVie include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Abbott Laboratories (ABT), Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK), Pfizer (PFE), and Zoetis (ZTS). These companies are all part of the "medical" sector.
AbbVie vs. Its Competitors
Amgen (NASDAQ:AMGN) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.
AbbVie has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.
Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. AbbVie pays an annual dividend of $6.56 per share and has a dividend yield of 3.5%. Amgen pays out 86.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie pays out 279.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has increased its dividend for 14 consecutive years and AbbVie has increased its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
Amgen has a net margin of 17.39% compared to AbbVie's net margin of 7.31%. AbbVie's return on equity of 412.03% beat Amgen's return on equity.
76.5% of Amgen shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 0.8% of Amgen shares are held by insiders. Comparatively, 0.3% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Amgen presently has a consensus price target of $307.82, indicating a potential upside of 3.21%. AbbVie has a consensus price target of $211.29, indicating a potential upside of 11.50%. Given AbbVie's stronger consensus rating and higher probable upside, analysts plainly believe AbbVie is more favorable than Amgen.
Amgen has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500.
In the previous week, AbbVie had 38 more articles in the media than Amgen. MarketBeat recorded 97 mentions for AbbVie and 59 mentions for Amgen. Amgen's average media sentiment score of 1.07 beat AbbVie's score of 1.06 indicating that Amgen is being referred to more favorably in the media.
Summary
AbbVie beats Amgen on 13 of the 20 factors compared between the two stocks.
Get AbbVie News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ABBV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NYSE:ABBV) was last updated on 7/6/2025 by MarketBeat.com Staff
Free ABBV Stock Alerts